Cardiovascular Risk Prediction in Psoriasis: Role of Biomarkers
Biomarkers hold promise for predicting cardiovascular risk in patients with psoriatic disease, facilitating risk stratification and guiding personalized management strategies to mitigate the heightened cardiovascular burden associated with psoriasis.
November 2022
Sarcopenia Identified as Comorbidity in Cardiovascular Disease
Sarcopenia, characterized by muscle loss and weakness, is identified as a comorbidity in cardiovascular disease, with multiple biological mechanisms contributing to its development and progression, underscoring the importance of integrated management approaches.
November 2022
Sex-Related Outcomes in Coronary Heart Disease Treatment Evaluated
Sex-related differences exist in medical, percutaneous, and surgical interventions for coronary artery disease, highlighting the need for gender-specific approaches to optimize treatment outcomes and reduce cardiovascular disparities.
November 2022
Blood Pressure Hyperresponsiveness to Standing: Implications for Cardiovascular Risk
An increase in systolic blood pressure of more than 6.5 mm Hg when standing is associated with increased cardiovascular risk, underscoring the clinical significance of orthostatic blood pressure changes in cardiovascular health assessment.
November 2022
Heart Complications Rare but Treatable After COVID-19 in Children and Young Adults
Heart complications following COVID-19 illness are rare but treatable in children and young adults, emphasizing the importance of post-acute care services and cardiac monitoring to detect and manage sequelae of COVID-19 infection.
November 2022
Stroke-Heart Syndrome: Understanding Cardiac Complications After Stroke
Cardiac complications following a stroke increase the risk of future cardiovascular events, highlighting the importance of comprehensive cardiovascular assessment and management in stroke survivors to reduce morbidity and mortality associated with stroke-heart syndrome.
November 2022
Age and Sex Influence Trends in Myocardial Infarction Incidence
The incidence of myocardial infarction declines more rapidly among individuals over 70 years of age, highlighting age and sex disparities in cardiovascular risk and the need for targeted prevention and management strategies.
November 2022
Inhaled Flecainide for Atrial Fibrillation Conversion: Novel Oral Inhalation Formulation
Oral inhaled flecainide acetate emerges as a potential therapeutic option for acute conversion of new-onset symptomatic atrial fibrillation to sinus rhythm, offering a convenient and effective treatment modality for rhythm control in selected patient populations.
November 2022
Exercise Guidelines Emphasize Reduction of Sedentary Time in Diabetes Management
Guidelines for exercise and physical activity in diabetes management prioritize the reduction of sedentary time, highlighting the importance of incorporating regular physical activity and minimizing prolonged sitting to optimize glycemic control and cardiovascular health.
November 2022
High Cardiovascular Risk in Patients with Mental Illness: Early Intervention Strategies
Early identification and management of cardiovascular risk factors are crucial in patients with mental illness to mitigate the heightened cardiovascular risk associated with psychiatric conditions and improve long-term cardiovascular outcomes in this vulnerable population.
November 2022
